HC Wainwright & Co. initiated coverage of LB Pharmaceuticals (NasdaqGM:LBRX) with a Buy rating on April 27, 2026. Fintel says the analyst price forecast implies 47.02% upside from current levels. The note is positive for sentiment, but it is routine analyst coverage and likely has only a modest near-term market impact.
HC Wainwright & Co. initiated coverage of LB Pharmaceuticals (NasdaqGM:LBRX) with a Buy rating on April 27, 2026. Fintel says the analyst price forecast implies 47.02% upside from current levels. The note is positive for sentiment, but it is routine analyst coverage and likely has only a modest near-term market impact.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.32
Ticker Sentiment
